Knauf C, Cani PD, Kim DH et al.
Centre Hospitalier Universitaire Rangueil, Toulouse, France.
Diabetes 2008;57:2603–12.
[2] Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity.
Cabou C, Campistron G, Marsollier N et al.
Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Diabetes 2008;57:2577–87.
Editor’s note: Although glucagon-like peptide type 1 (GLP-1)-based therapies are now well established in the treatment of type 2 diabetes, the role of GLP-1 in the central nervous system (CNS) is not yet fully understood. The first of these two studies investigated the role of CNS GLP-1 in relaying the “sensing” of glucose in the gut [1]. Glucose was infused into the stomachs of wild-type and GLP-1 receptor-knockout mice, resulting in increased muscle glycogen synthesis. This effect was blocked by CNS infusion of the GLP-1 antagonist exendin-9 (Ex9) in the wild-type mice, but Ex9 infusion had no impact in the GLP-1 receptor-knockout mice.